One of the major unanswered questions in hypertension research is the mechanism of vascular hypertrophy. It has been proposed that this structural adaptation of the blood vessel may play an important role in reducing arterial wall tension and in amplifying hypertension. The factors that initiate and maintain blood vessel hypertrophy have not been fully elucidated. Since angiotensin has been shown to induce a growth response in cultured vascular smooth muscle cells (VSMC), we hypothesize that during the development of chronic hypertension, the local production of angiotensin may be responsible for the hypertrophic response of the blood vessel. To examine this possibility, the vascular wall renin angiotensin system will be characterized and the level of renin and angiotensinogen mRNA expressions will be determined. To link vascular angiotensin activation with vascular hypertrophy, the effects of converting enzyme inhibitor (or angiotensin antagonist) vs nonspecific vasodilator (hydralazine) (titrated to comparable blood pressure reduction) on vascular hypertrophy will be compared. This will allow one to examine whether angiotensin is responsible for the increased blood vessel mass in hypertension. In order to understand the molecular mechanism of angiotensin induced hypertrophy, its effect on c-fos and PDGF expressions will be studied. We propose to study c-fos based on the recent data that AII stimulated c-fos mRNA in VSMC and that c-fos is important in 3T3 fibroblast growth and proliferation. The transcriptional regulation of the c-fos gene including the elements responsible for AII responsiveness will be examined in detail. Documentation of the importance of this mechanism on VSMC growth will be carried out by blocking c-fos mRNA using a c-fos antisense expression vector. To examine the contribution of PDGF expression, we will also block PDGF expression using a PDGF antisense expression vector and determine the effect on VSMC growth and hypertrophy. In addition, the interaction of AII with other contractile agonists (e.g. norepinephrine) on vascular hypertrophy will be studied in hypertension. The above experiments should define the role of vascular angiotensin in the hypertrophy of blood vessels and provide insight into the molecular mechanism of this vascular hypertrophy.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL042663-01
Application #
3360991
Study Section
Cardiovascular and Pulmonary Research B Study Section (CVB)
Project Start
1989-04-01
Project End
1993-03-31
Budget Start
1989-04-01
Budget End
1990-03-31
Support Year
1
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Miller, M (2009) Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM 102:657-67
Tomita, N; Morishita, R; Tomita, S et al. (2000) Transcription factor decoy for NFkappaB inhibits TNF-alpha-induced cytokine and adhesion molecule expression in vivo. Gene Ther 7:1326-32
Pratt, R E (1999) Angiotensin II and the control of cardiovascular structure. J Am Soc Nephrol 10 Suppl 11:S120-8
Hutchinson, H G; Hein, L; Fujinaga, M et al. (1999) Modulation of vascular development and injury by angiotensin II. Cardiovasc Res 41:689-700
Pratt, R E; Dzau, V J (1999) Genomics and hypertension: concepts, potentials, and opportunities. Hypertension 33:238-47
Wu, C F; Bishopric, N H; Pratt, R E (1997) Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Biol Chem 272:14860-6
Dzau, V J; Gibbons, G H; Mann, M et al. (1997) Future horizons in cardiovascular molecular therapeutics. Am J Cardiol 80:33I-39I
Hutchinson, H G; Trindade, P T; Cunanan, D B et al. (1997) Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells. Cardiovasc Res 35:158-67
Hein, L; Stevens, M E; Barsh, G S et al. (1997) Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci U S A 94:6391-6
Zhang, J; Pratt, R E (1996) The AT2 receptor selectively associates with Gialpha2 and Gialpha3 in the rat fetus. J Biol Chem 271:15026-33

Showing the most recent 10 out of 50 publications